HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
5.50
+0.28 (5.36%)
Jun 12, 2025, 4:00 PM - Market closed
HCW Biologics Revenue
HCW Biologics had revenue of $5.07K in the quarter ending March 31, 2025, a decrease of -99.55%. This brings the company's revenue in the last twelve months to $1.45M, down -63.20% year-over-year. In the year 2024, HCW Biologics had annual revenue of $2.57M, down -9.68%.
Revenue (ttm)
$1.45M
Revenue Growth
-63.20%
P/S Ratio
45.31
Revenue / Employee
$40,143
Employees
36
Market Cap
9.58M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
HCWB News
- 8 days ago - HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech - GlobeNewsWire
- 4 weeks ago - HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 4 weeks ago - HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 4 weeks ago - HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization - GlobeNewsWire
- 2 months ago - HCW Biologics Announces 1-for-40 Reverse Stock Split - GlobeNewsWire
- 2 months ago - HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results - GlobeNewsWire
- 3 months ago - HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements - GlobeNewsWire
- 4 months ago - HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial - GlobeNewsWire